Eton Pharmaceuticals, Inc.
ETONHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jun 1, 2026
Scan Results
Daily timeframeEton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Valued at $834.1M, ETON is a small-cap name in its sector. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Market Cap
$834.1M
Beta
0.82
P/E (TTM)
—
P/E (Fwd)
16.20
EPS (TTM)
$-0.06
EPS (Fwd)
$1.88
ROE
-5.4%
ROA
4.8%
Cash
$19.7M
Total Debt
$31.3M
Free CF
$2.4M
52W Change
61.6%
Annual Financials
Cash vs Debt
Eton Pharmaceuticals, Inc. carries $31.3M in total debt against $19.7M in cash reserves — debt is roughly 1.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $2.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -5.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $21.3M (2022) to $80.0M (2025), reflecting a 276% increase over the period.
Investors considering Eton Pharmaceuticals, Inc. should weigh the typical risks associated with ETON's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing ETON's risk profile alongside its fundamentals and technical indicators provides a more complete picture.